Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
CTC Bio starts phase I for orally-disintegrating donepezil
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Aug 1, 2013 12:26:26
CTC Bio is starting its phase I clinical trial for orally-disintegrating films (ODFs) of donepezil soon as the Ministry of Food and Drug Safety approved its study protocol, sources said Monday.

If everything goes well as planned, donepezil ODF can be available in October or November 2013. CTC Bio expects three Korean pharmaceutical companies to co-market its new product with three partner companies although only one company has been signed up so far.

An official of CTC Bio said, “We finished up the preparation for manufacturing. As soon as the contracts are made with more companies, we plan to roll it out.”

Donepezil patches are being developed, too. Once patches and orally disintegrating films of donepezil reach the market, the market landscape will be changed, industry experts said.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com